clear orr hurdl gvhd
today announc result phase pivot trial jakafi
acut gvhd studi show orr day surpass
expect snda present complet data upcom
scientif confer includ durabl data could import
approv overal believ today data posit rais
likelihood success jakafi acut ghvd increas
confid around pipelin consequ reiter buy
rais pt
jakafi data look posit orr day look forward
detail data upcom scientif confer snda file
today announc posit result singl
arm patient phase pivot trial jakafi steroid refractori acut gvhd
orr day primari endpoint best
orr respons time studi secondari endpoint
common treatment emerg advers event grade
anemia thrombocytopenia neutropenia
remind program conduct breakthrough design
view signific posit program clear pre-specified
hurdl orr secondari endpoint trial includ
durat respons durat respons nonrelaps
mortal protocol-defin timepoint incid sever advers
event believ day orr clear
encourag look forward durat data full data present
upcom scientif confer manag note durabl
import incyt plan file snda jakafi steroid refractori
acut gvhd base result rais probabl
success jakafi gvhd
run two addit trial gvhd collabor
novarti nv rate european partner jakafi
on-going random patient trial acut gvhd
intend support approv europ reach patient random
studi jakafi vs physician choice/best avail therapi control
also run collabor novarti patient
model chang increas likelihood success jakafi
gvhd ad pt jakafi
technolog valu base upon today pipelin success consequ pt
rise
tr target
catalyst focu molecul capmatinib cmet phase data nsclc
initi phase data cholangiocarcinoma furthermor expect
addit color afternoon analyst day
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt jakafi
mf pv gvhd olumi iclusig cash/technolog
bull/bear case model yield pt risk includ failur epacadostat competit
impact jakafi olumi uptak
page
data catalyst next month highlight
page
candidatetargettim mileston settingpartnerepacadostat durvalumab data solid tumorsio data pair biopsi trial multipl tumor datasolid datasolid initi pivot programpsoriat arthritis phase glioblastoma liver cancer incyt corpor
page
 epacadostat- jakavi olumiant- olumi mileston number factset managementvaluationfromtochangediscount adjust sale probabl success weight weight epacadostat- technolog corpor
page
page
quarterli sale iclusig cml- product olumi ra us- ra row- fair valu acquisit incom incom non-gaap inc net incom non-gaap ex incom share outstand corpor
page
annual jakafi gvhd/transplant- iclusig cml- total product total fair valu acquisit incom interest incom non-gaap ex incom share outstand corpor
commerci stage biotech compani believ gener signific cash flow
two partner asset develop deep pipelin oncolog asset incyt commerci asset jakafi
could see upsid addit indic fulli partner arthriti molecul olumi
launch would help fund well posit immuno-oncolog target molecul
jakafi above-p biotech growth addit upsid new indic jakafi rapidli
grow drug myelofibrosi polycythemia vera project revenu
jakafi drug show durabl effect clinic benefit importantli jakafi
also shown encourag clinic benefit graft vs host diseas project peak
sale additoin valu come baricitinib non-oncolog rheumatoid arthriti ra focus cash
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt jakafi mf pv gvhd
olumi iclusig cash/technolog bull/bear case model yield
pt risk includ failur epacadostat competit impact jakafi olumi uptak
compani mention note
novarti nv rate
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
